PE-backed specialty pharma company Kelso Pharma appointed Giovanni Mauri as general manager of its recently acquired Italian ...

A growing momentum for earlier treatment of psoriasis has the potential to improve outcomes with oral therapies and biologics used to treat psoriasis, said Strober. The momentum can be traced to an ...

The drug is a recombinant version of the enzyme ... of glycogen to toxic levels that damage muscle cells. Sanofi's Genzyme rare diseases division already sells another enzyme replacement therapy ...

Viridian Therapeutics, Inc. , a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff ...

Correspondence to Professor Maria A Rocca, Neuroimaging Research Unit, Division of Neuroscience, IRCCS Ospedale San Raffaele, Milano 20132, Italy; rocca.mara{at}hsr.it PRLs are considered relatively ...

Liquidia Corporation announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat ...

In this video, Peter Lio, MD, discussed updates on topical agents, biologics and drugs in the pipeline in atopic dermatitis from presentations at the American Academy of Dermatology meeting.

The Notice of Meeting and Proxy Statement on the following pages describe the matters to be presented at the Annual Meeting. Please see the section called "Who can attend the Annual Meeting?

She was speaking after two men were convicted of being involved in the killing of a 37-year-old drug "runner" Dean Fountaine, from Leighton Buzzard. Peter Janoski, 44, has been found guilty of murder ...